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Abstract
Background: It is generally assumed that most patients with celiac disease (CD) have a slowed
growth in terms of length (or height) and weight. However, the effectiveness of slowed growth as
a tool for identifying children with CD is unknown. Our aim is to study the diagnostic efficiency of
several growth criteria used to detect CD children.
Methods:  A case-control simulation study was carried out. Longitudinal length and weight
measurements from birth to 2.5 years of age were used from three groups of CD patients (n =
134) (one group diagnosed by screening, two groups with clinical manifestations), and a reference
group obtained from the Social Medical Survey of Children Attending Child Health Clinics
(SMOCC) cohort (n = 2,151) in The Netherlands. The main outcome measures were sensitivity,
specificity and positive predictive value (PPV) for each criterion.
Results: Body mass index (BMI) performed best for the groups with clinical manifestations. Thirty
percent of the CD children with clinical manifestations and two percent of the reference children
had a BMI Standard Deviation Score (SDS) less than -1.5 and a decrease in BMI SDS of at least -2.5
(PPV = 0.85%). The growth criteria did not discriminate between the screened CD group and the
reference group.
Conclusion:  For the CD children with clinical manifestations, the most sensitive growth
parameter is a decrease in BMI SDS. BMI is a better predictor than weight, and much better than
length or height. Toddlers with CD detected by screening grow normally at this stage of the
disease.
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Background
One of the goals of growth monitoring in developed
countries is the detection of undiagnosed illnesses. Never-
theless, there is little consensus on which referral criteria
for children with growth retardation are appropriate [1].
Recently we reported on the predictive value of various
growth criteria for the detection of Turner's syndrome [2].
The focus of that study was on short stature and slowed
growth for length or height, as short stature is the main
common physical characteristic of Turner's syndrome.
Growth retardation, however, may also imply failure to
thrive in terms of slowed growth for weight and BMI.
Celiac disease (CD), also known as gluten-sensitive enter-
opathy, is characterized by subtotal villous atrophy of the
small intestine, intra-epithelial lymphocytosis and crypt
hyperplasia, and is associated with a variable mode of
presentation. The classical presentation is characterized by
failure to thrive, diarrhoea, irritability, vomiting, ano-
rexia, foul stools, abdominal distension and muscle wast-
ing. However, many infants, toddlers and children with
celiac disease present with few or no signs and symptoms
[3-6]. The prevalence of the classical presentation of CD
decreased in the past decade, while the prevalence of non-
classical presentations increased [3-5]. Growth failure in
terms of length (or height) or weight may be the earliest
sign of the disease [7]. In 1994, the reported incidence of
clinically diagnosed CD in the Netherlands was 0.54 per
1000 live births [8]. However, screening studies using
detection of anti-endomysium antibodies have shown a
much higher prevalence (1:300 to 1:100). The ratio of
clinically diagnosed versus CD detected by screening var-
ies between 1:7 and 1:14 [9]. Early detection and treat-
ment with a gluten-free diet is required to improve the
immediate quality of life of the CD patients and to
decrease the long-term risks, including reduction in adult
height, a higher prevalence of malignancies, adverse preg-
nancy outcome, neurological problems and osteomalacia
[10].
Mass screening for CD using specific antibodies is unlikely
to be performed, because of the uncertainty concerning
the cost-benefit ratio. As there is a high incidence of CD
(1.7 to 8.3%) in children with growth retardation without
gastrointestinal symptoms and even higher (up to 59.1%)
when other (endocrine) causes for short stature are
excluded [7], a substantial proportion of infants and chil-
dren with CD may be detected through growth monitor-
ing.
In the Netherlands, nearly every child is monitored for
height and weight from birth till the age of 16–18 years.
Children with abnormal growth are referred to secondary
health care providers according to certain criteria [11]. As
no pathologic causes for short stature were detected in
most of these referred children, we recently revised the
referral criteria. These criteria minimize the unnecessary
referrals and are aimed at not missing important diseases
such as CD, Turner's syndrome and endocrine abnormal-
ities [12].
So far, it is generally assumed that most CD patients have
a slowed growth in terms of length (or height) and weight
[13]. However, the effectiveness of slowed growth as a
tool for identifying children with CD is unknown. The
aim of this study is to establish optimal referral criteria
based on abnormal growth for detecting asymptomatic
and symptomatic children with CD.
Methods
Patients
Longitudinal length and weight data of patients with CD
were collected from three different studies. The first study
was a prospective screening study using blood tests in
unrecognized CD in children aged 2–4 years, visiting the
Community Child Health Care Centers in the Dutch prov-
ince of Zuid (South)-Holland [9]. In this study, 32 chil-
dren with CD were detected between May 1997 and June
1998. The second study was a retrospective study on catch
up growth in patients with CD [13]. A written question-
naire including their symptomatology, duration of com-
plaints before diagnosis, age at diagnosis, associated
diseases in the past and parental heights was sent to all
members of the Dutch Celiac Society in the early nineteen
eighties. Growth data were collected from 74 children
younger than 16 years. The third study was a prospective
study on catch up growth [14]. All newly diagnosed child-
hood CD patients from two separate pediatric depart-
ments were included between April 1994 and September
1995 (n = 28). The children in the second and third study
presented with a full range of classical symptoms. We used
all growth data before and at the start of the gluten-free
diet, till the age of 2.5 years. The data was gathered retro-
spectively from child welfare clinics, pediatricians and
general practitioners. Additional growth information of
these children was obtained from physicians in the
Regional Child Health Care Centres. The diagnosis of CD
was confirmed by histology for all patients, although in
the retrospective study we were dependent on the infor-
mation provided by patient reports. In total, we included
134 children: 32 children from the first study, 74 children
from the second study and 28 children from the third
study. Exclusion criteria were: an unknown date of start-
ing the gluten-free diet and no measurement between
birth and 2.5 years of age. After excluding such cases, 122
children were eligible for further analyses: 26 children
from the first study and 96 children from the second and
third study (see Figure 1).BMC Pediatrics 2008, 8:35 http://www.biomedcentral.com/1471-2431/8/35
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The first CD group was asymptomatic or featured symp-
toms that were not signalled by the parents or the general
practitioners. Therefore, this group was analyzed sepa-
rately (screened group). The second and third CD groups
were clinically diagnosed and we reasoned that these two
groups could be pooled (symptomatic group).
Reference sample
A reference sample was obtained from the Social Medical
Survey of Children Attending Child Health Clinics
(SMOCC) cohort, a nationally representative cohort of
2,151 children born in the Netherlands during 1988–
1989 [15]. Of this cohort longitudinal data of length and
weight of children from birth to 2.5 years of age were
available. The length and weight from birth to two years
of these children were previously described by Herngreen
et al.[16].
Power analysis
For an estimated sensitivity of 50% we obtained a 95%
confidence interval (95%-C.I.) of +/- 19% with the 26
screened CD children and +/- 10% with the 96 sympto-
matic CD children. For an estimated specificity of 98% we
obtained a 95%-C.I. of +/- 0.6% with the 2,151 reference
children.
Screening rules
We formulated several screening rules for growth that
could serve as criteria for referral to specialist care (Table
1). Each of these rules combines several parameters, such
as starting age or a decrease in standard deviation score
(SDS) over a certain time period. Table 1 explains the
interpretation of each parameter. We used several simula-
tion values for each parameter to see how the diagnostic
performance of each rule changes. For example, for the
parameter starting age, we used simulation values of 0, 1/
2 and 1 year of age. These simulation values were chosen
to investigate if the growth pattern of CD children starts to
deviate from the reference population already at birth (0
year), or at the time children commence to eat gluten (1/
2 year) or later (at 1 year).
In total, we formulated eight rules, and each rule is
explained in detail in Table 1 and below.
1. The first rule (delta rule) refers a child if an absolute
change in length SDS, weight SDS or BMI SDS occurs. For
example, suppose a child has two weight measurements,
one measurement at the age of six months and one at the
age of 1.5 years. This child will then be referred according
to the delta rule with parameters e1 = 0.5 and g1 = -2 (see
Table 1) if his or her weight decreases by more than 2 SDS
between the first and the second measurement.
2. The second rule (extended delta rule) is equal to the first
rule with the extension that the second measurement has
to have a low SDS (for example less than -1.5 SDS).
3. The third rule (slowed growth rule) signals whether an
abnormal slowed growth for length, weight or BMI occurs
in terms of change in SDS per year in combination with a
current low SDS. For example, suppose a child has two
length measurements, one measurement at the age of
seven months and one measurement six months later.
This child will then be referred according to the slowed
growth rule with parameters e3 = 0.5, g3 = -1 and f2 = -1.5
(see Table 1) if the difference between the second and first
length measurement per year exceeds 1 SDS (which corre-
sponds to a decrease of 0.5 SDS within six months) and if
the second measurement is less than -1.5 SDS. We prefer
the term slowed growth over the term velocity to indicate
the decrease in growth in SDS per year. The term velocity
commonly refers to cm or kg/year.
4. The fourth rule (conditional weight gain rule) is the con-
ditional weight gain rule that signals whether a child's
conditional weight gain SDS is less than a certain value
[17,18] with the restriction of having a low weight SDS.
5. The fifth rule (absolute SDS rule) refers a child if the
length SDS, weight SDS or BMI SDS is low. An example is
to refer if a child's length SDS is less than -2 (e5 = 0 and f5
= -2).
6. We also considered rules that take genetic height poten-
tial into account. The sixth rule (parental height corrected
Flow chart of children with CD used in the study Figure 1
Flow chart of children with CD used in the study.
n=134 
n =10 
Unknown date of starting gluten-free diet 
n=124 
n=2 
No measurement before age 2.5 
years 
n=122 
n=26 screened children 
(group 1) 
n=96 children with clinical manifestation  
of celiac disease (groups 2&3) BMC Pediatrics 2008, 8:35 http://www.biomedcentral.com/1471-2431/8/35
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Table 1: Growth screening rules with their definitions, interpretation of the used parameters and cut off (simulation) values (see 
method for details)
Screening rule Definition Parameter Interpretation Simulation values
Delta rule*^ For ages e1 to 2.5 years, refer if e1 Age (in years) after which the 
rule is effective
0, 0.5, 1
(SDS2 – SDS1) <g1 g1 Change in SDS -0.5,-1,-1.5,-2,-2.5,-3
Extended delta rule* For ages e2 to 2.5 years, refer if e2 Age (in years) after which the 
rule is effective
0, 0.5, 1
SDS2<f1, AND f1 SDS cut off level below which the 
SDS2 must lie
-1,-1.3, -1.5,-2, -2.5
(SDS2 – SDS1) <g2 g2 Change in SDS -0.5,-1,-1.5,-2,-2.5,-3
Slowed growth * For ages e3 to 2.5 years, AND e3 Age (in years) after which the 
rule is effective
0, 0.5, 1
X2 – X1 ≥ 3/12 refer if Minimal three months interval 
between ages X1 and X2
SDS2<f2, AND f2 SDS cut off level below which the 
SDS2 must lie
-1,-1.3, -1.5,-2, -2.5
(SDS2- SDS1)/(X2-X1) < g3 g3 Change in SDS per year -0.5,-1,-1.5,-2,-2.5
Conditional weight gain rule For ages e4 to 2.5 years, refer if e4 Age (in years) after which the 
rule is effective
0, 0.5, 1
weight SDS2 <f3 AND f3 SDS cut off level below which 
SDS2 must lie
-1,-1.3, -1.5,-2, -2.5
weight SDSgain = (weight SDS2 – 
r weight SDS1)/(√1-r2) <g4
g4 Change in SDS -0.5,-1,-1.5,-2,-2.5
Absolute SDS rule* For ages 0 to e5 years, refer if e5 Age (in years) at which the 
referral level changes
0, 0.5, 1
SDS <f4 f4 SDS cut off level before age e5 -1, -1.3, -1.5, -2, -2.5, -3, -3.5
For ages e5 to 2.5 years, refer if 
SDS <f5
f5 SDS cut off level after age e5 -1, -1.3, -1.5, -2, -2.5, -3
Parental height corrected rule For ages e6 to 2.5 years, refer if e6 Age (in years) after which the 
rule is effective
0, 0.5, 1
length SDS <f6, AND f6 Length SDS must lie below this 
cut off level
-1, -1.3, -1.5, -2, -2.5
length SDS – TH SDS <g5 g5 Difference between length SDS 
and target height (TH) SDS
-1, -1.3, -1.5, -2, -2.5
Parental height deflection rule For ages e7 to 2.5 years, refer if e7 Age (in years) after which the 
rule is effective
0, 0.5, 1
(length SDS2 – length SDS1) <g6, 
AND | length SDS2 – TH SDS | > 
| length SDS1 – TH SDS |
g6 Change in length SDS Length SDS 
at age X1 is closer to it's target 
height than length SDS at age X2
-0.5,-1,-1.5,-2,-2.5,-3
Combined weight and length 
deflection rule
For ages e8 to 2.5 years, AND e8 Age (in years) after which the 
rule is effective
0, 0.5, 1
(weight SDS2 – weight SDS1) <g7, 
AND
g7 Weight change in SDS -0.25,-0.5,-1,-1.5,-2
(length SDS2 – length SDS1) <g8, 
AND Y1 > X1
g8 Length change in SDS Starting 
point length deflection (Y1) after 
starting point weight deflection 
(X1)
-0.25,-0.5,-1,-1.5,-2
Several screening rules for growth were studied. Each screening rule consists of parameters that we have varied. For more details, see the 
paragraph screening rules.
* Calculated for length (height), weight, and BMI
^For example, if e1 = 0.5 year and g1 = -2 weight SDS, then a child is referred if the second weight SDS measurement is -2 below the first weight SDS 
measurement and both weights were measured after six months of age (or at six months of age for the first measurement).BMC Pediatrics 2008, 8:35 http://www.biomedcentral.com/1471-2431/8/35
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rule) compares the height SDS of the child to its target
height SDS in combination with a low height SDS.
7. The seventh rule (parental height deflection rule) signals
whether a slowed growth for length SDS of the child
moves away from the child's target height. This rule was
added because of the assumption that a correction might
be needed for parental height in the first years of life: e.g.
a baby that is born with a length SDS of -1 and has a target
height SDS of +2, would be expected to cross the SD lines
in upward direction in the first 2–3 years. A growth disor-
der could disturb this, and a stable length SDS of this child
at -1 over the first 2 years could indicate growth pathology
such as CD.
8. Similarly, in the eight rule (combined weight and length
deflection rule) we combined weight and length, in which
a slowed growth for length occurs after a slowed growth
for weight.
Several cut off values for age were used as the effectiveness
of these rules may increase by examining higher age
groups. Slowed growth requires measurements taken at
least three months apart. We chose this short time interval
to facilitate early detection, taking into consideration that
children in the first year of life grow faster than in later
years.
It should be noted that some parameters select a subset of
the data and assume multiple measurements. The rules
were only tested on children that complied with these
assumptions. All available pairs of measurements for each
infant were used.
Statistical analysis
Each screening rule was implemented using S-Plus version
7.0.3 for Microsoft Windows (2005), and was applied to
the longitudinal data of children. We calculated sensitiv-
ity, specificity and positive predictive value (PPV) for each
rule with several scenarios (simulation values). The rules
were ordered according to their sensitivity at high levels of
specificity. A higher sensitivity at the same level of specif-
icity, results in a better performance. The results were plot-
ted as a Receiver Operating Characteristic (ROC) curve,
but scaled to a different axis than conventionally in order
to view the area of most interest (high specificity). Each
point in the ROC curve is the false-positive rate against
sensitivity of a scenario (combination of simulation val-
ues) of a rule. Scenarios of rules with approximately 2%
false-positive rates were presented in detail as we assumed
that a false-positive rate greater than 2% would result in
too many referrals. PPV was calculated assuming that the
incidence of CD is 0.54 per 1000 live births in the Cauca-
sian population [9]. Sensitivity analyses were performed
to calculate the effect of small variations (0.1–1.0/1000)
in the incidence of CD on PPV.
Length, weight and BMI were expressed as SDS, using the
Dutch reference growth data [19,20]. In preterm infants
(gestational age < 37 weeks) length and weight SDS were
corrected for gestational age. The intrauterine growth
charts from the Swedish reference population was used to
express SDS up to the age corresponding with 40 weeks of
gestation [21]. Between 40 and 42 weeks an interpolation
between the growth curve of the Swedish reference popu-
lation and that of the Dutch reference population was
used. From 42 weeks of gestation till the age of 2 years,
SDS was calculated on ages corrected for gestational age,
using the Dutch reference growth data.
We assumed that a child was referred if the growth pattern
met the criteria of a given screening rule for the first time.
All rules were dealt with separately, meaning that the
same child could be referred according to each separate
rule.
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Results
Table 2 contains general characteristics of the sympto-
matic CD group and the screened CD group. In the symp-
tomatic group, mean weight SDS was compromised most,
followed by mean BMI SDS.
Diagnostic performance of the rules: screened CD children
All screening rules detected less than 5% of the screened
CD children at a 2% false-positive rate. Therefore, none of
the rules were able to discriminate between the CD chil-
dren detected by screening and the reference children.
This indicates that the screened and the reference children
hardly differ in terms of their growth pattern.
Diagnostic performance of the rules: symptomatic CD 
children
The results are different for the symptomatic CD children.
Figure 2 shows the ROC plot for the four best screening
rules for the symptomatic CD group. Only scenarios with
a false-positive rate of less than 10% are plotted. The line
for which sensitivity is equal to 100-specificity is given in
the figure. Scenarios on this line are not able to discrimi-
nate between the CD and the reference group. The BMI
extended delta rule had the highest sensitivities at low
false-positive rates. A strict version of this rule is a decrease
in BMI SDS of -3 and a BMI SDS less than -1 between birth
and 2.5 years of age. This scenario correctly identifiedBMC Pediatrics 2008, 8:35 http://www.biomedcentral.com/1471-2431/8/35
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21% (95%-CI 12–30) of the CD children and 99% (95%-
CI 98.6–99.4) of the reference children were correctly
labelled as disease free. The PPV of this scenario is approx-
imately 1%. For example, suppose a boy has a BMI on the
line above the median of the growth chart (SDS = +1) at
three months of age. If he crosses three SDS lines (SDS 0,
-1 and -2) before the age of 2.5 years, then the boy has a
1% probability of having CD. A less strict version of the
BMI extended delta rule is a decrease in BMI SDS of at
least -2 and a BMI SDS of less than -1.5 between birth and
2.5 years of age, with a sensitivity of 38% (95%-CI 27–
49), a false-positive rate of 3.4% (95%-CI 2.6–4.2) and a
PPV of 0.60%.
The properties of the four best rules for the symptomatic
CD group, in terms of sensitivity and PPV at approxi-
mately 98% specificity, are presented in table 3. Thirty
percent (95%-CI 20–40) of the CD children and 1.9%
(95%-CI 1.3–2.5) of the reference children had a decrease
in BMI SDS of at least -2.5 and a BMI SDS less than -1.5
between birth and 2.5 years of age. In children with such
decrease in BMI SDS, the probability of CD is 0.85%. PPV
varied between 0.16% and 1.57% when changing the inci-
dence of CD from 1:10000 to 1:1000 live births. For
example, a girl has a BMI on the median of the growth
chart at one month of age, and her BMI crosses centiles for
a certain time period until she reaches a BMI SDS of less
than -2.5. Then this girl will be referred according to the
scenario above. Her probability of actually having CD is
0.85%. Furthermore, 27% (95%-CI 16–38) of the CD
children versus 1.9% (95%-CI 1.3–2.5) of the reference
children had a decrease in BMI SDS of at least -1.5 when
they were older than six months of age. The probability of
having CD when a child complies with this rule is 0.76%.
Both the slowed growth for BMI rule and the conditional
weight gain rule result in a sensitivity of approximately
22% (95%-CI 11–33) at a false-positive rate of 1.9%
(95%-CI 1.3–2.5). The PPV is approximately 0.6%. The
sensitivity between the first rule (the BMI extended delta
rule) and the fourth rule (conditional weight gain rule)
differed most. Twenty percent of the CD children com-
plied with the first rule (true-positive) and not with the
fourth rule (false-negative), while ten percent of the CD
children complied with the fourth rule and not with the
first rule. If we combine both rules, sensitivity is 41%.
However, the false-positive rate also increased to 3.6%.
The delta rules for length and weight, the slowed growth
rule for length and weight, the absolute SDS rule, rules
Table 2: General characteristics of the CD-population
Characteristic Screened (n = 26) Symptomatic (n = 96)




Median (range) age in years at start diet 3.96 (2.94–6.06) 1.43 (0.41–20.7)
Mean (SD) length SDS *∞ -0.26 (0.98) -0.89 (1.30)
Mean (SD) weight SDS*∞ -0.06 (0.81) -1.54 (1.15)
Mean (SD) BMI SDS*∞ 0.28 (0.57) -1.28 (1.15)
Mean (SD) target height SDS 0.41 (0.92) 0.00 (0.75)
* For the children in the screened group figures at diagnosis are given (also when diagnosis is after 2.5 years of age). For the symptomatic CD 
children figures at the start of the gluten-free diet are given.
∞ Based on children with at least one measurement between 6 months before and 3 months after gluten-free diet or diagnosis.
ROC plot of effective growth screening rules for detecting  CD in the symptomatic group Figure 2
ROC plot of effective growth screening rules for 
detecting CD in the symptomatic group. The rules are 
an absolute change in BMI SDS with or without the restric-
tion of a low BMI SDS, a slowed growth for BMI, and a condi-
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Slowed growth for BMI rule
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that take genetic height potential into account (parental
height corrected rule and parental height deflection rule)
and the combined weight and length deflection rule
proved less effective (data not shown). At a fixed specifi-
city of 98%, sensitivities for these rules were less than
20%.
Discussion
Our study shows that for detecting or predicting sympto-
matic CD children by growth, a decrease in BMI is more
informative than a decrease in weight or length. The
screened CD children grow normally between birth and
2.5 years of age.
The optimal weight rule in this study was the conditional
weight gain rule. The conditional weight gain rule corrects
for regression to the mean. The amount of regression to
the mean depends on the correlation of body weight
across age [17]. The correlations that we used in our study
were based on children in the UK [18]. The conditional
weight gain rule may perform better when using correla-
tions of Dutch children. However, these correlations are
presently not available. To validate the UK correlations for
the Dutch children, we calculated if the SDSgain has a
mean of zero and a SD of 1, and if it is uncorrelated with
the first weight SDS. For the reference group of Dutch chil-
dren, the mean (SD) SDSgain is -0.06 (1.41) and its corre-
lation with the first weight SDS is -0.23. As both SD and
correlation are quite high, the conditional weight gain
rule may perform better when using Dutch correlations of
weights. Furthermore, a rule based on BMI that corrects
for regression to the mean may improve discrimination
between the symptomatic CD group and the reference
group. So far no suitable correlations have been published
to calculate this conditional gain.
In this study, PPV of the screening rules may be underes-
timated for several reasons. Firstly, PPV will be slightly
higher as there will be one case of CD in our reference
group if we assume that the incidence of CD is 0.54 per
1000 life births. Secondly, PPV was calculated using only
the incidence of CD. However, if we keep in mind that
children with genetic disorders or diseases other than CD
may be detected by some of our rules for failure to thrive,
PPV may be higher. For example, if we assume that sensi-
tivity and specificity for the most optimal rule for CD in
this study is similar to patients with Cystic Fibrosis (CF),
then PPV will be higher if this is based on the incidence of
both CD and CF [22].
As Csizmadia et al. reported earlier, the children with CD
detected by screening had a normal weight and length at
time of diagnosis [9]. We have confirmed that all children
in this group indeed had a normal growth pattern
between birth and 2.5 years of age. This corresponds with
the asymptomatic character of this silent form of CD.
Thus monitoring growth would not seem to be useful for
the detection of silent CD at this specific stage of the dis-
ease. The prevalence of children with short stature and no
gastrointestinal symptoms investigated for CD is 2–8%
[7] compared to a prevalence of 1:300 to 1:100 in the gen-
eral population. Therefore, one may expect that these chil-
dren would develop abnormal growth after several years.
CD is often atypical or clinically silent, which results in
many undiagnosed children. However, since the wide-
spread introduction of serologic testing and the increased
awareness of CD in the late 1990s there has been an
increase in incidence as well as a change in clinical presen-
tation [3-6]. The classical symptoms, such as malabsorp-
tion and poor weight gain no longer dominate the clinical
picture. Instead, there is an increase of cases with non-
classical symptoms, including unusual intestinal com-
plaints or extra-intestinal symptoms (e.g. short stature)
involving older children. In addition, the age of presenta-
tion may be changing due to differences in infant feeding
practices, duration of breastfeeding and improved recog-
nition of potential CD by general practitioners. As our
non-screened population was diagnosed before 1995, we
were not able to study the effect of this change in time on
the performance of the growth criteria. However, one may
assume that for the age group included in our study, the
performance of the growth criteria is similar for the
present CD-population, as it is mainly the delayed onset
variant of the disease (the non-classical form) that has
increased during the recent years, suggesting that the
growth impairment becomes apparent much later.
Most of the patients in our study were females, as was
reported in several other studies [23]. Bardella et al.
Table 3: Simulation values and the percentage of detected CD children (sensitivity) with approximately 2% false-positives (= 98% 
specificity)
(symptomatic) CD Simulation values* Sensitivity (95%-CI) 100-Specificity (95%-CI) PPV
BMI extended delta rule e2 = 0 f1 = -1.5 g2 = -2.5 30 (20–40) 1.9 (1.3–2.5) 0.85%
BMI delta rule e1 = 0.5 g1 = -1.5 27 (16–38) 1.9 (1.3–2.5) 0.76%
Slowed growth for BMI rule e3 = 0 f2 = -2 g3 = -2.5 22 (11–33) 1.8 (1.2–2.4) 0.65%
Conditional weight gain rule e4 = 0.5 f3 = -2.5 g4 = -0.5 to -1.5 21 (12–30) 1.9 (1.3–2.5) 0.58%
*Table 1 explains the interpretation of the simulation valuesBMC Pediatrics 2008, 8:35 http://www.biomedcentral.com/1471-2431/8/35
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hypothesized that males escape diagnosis, but that the
two sexes are equally affected. This hypothesis is sup-
ported by the absence of differences in sex in the screening
study (see Table 2).
In conclusion, we support the clinician to consider testing
for CD in a diagnostic work-up in young children with
failure to thrive. The most sensitive growth parameter is
BMI SDS. We recommend further research with a large
sample of children with CD diagnosed in the last few
years to study the most valid simulation values for referral
rules based on BMI and other diagnostics.
Conclusion
BMI is more efficacious than weight, and much more than
length or height, in detecting symptomatic children with
CD. Toddlers with CD detected by screening grow nor-
mally at this stage of the disease.
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